Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.

MEMS, MDES kicks off heart disease-diabetes awareness campaign

Pank Jit Sin
12 Sep 2019
L-R: Prof. Dr Chee Kok Han, Siah Guan Jian, Dr Zanariah Hussein, and Ung Liew Ean, General Manager of Boehringer Ingelheim Malaysia & Singapore at the launch of For Your Sweetheart campaign.

The Malaysian Endocrine and Metabolic Society (MEMS) and Malaysian Diabetes Educators Society (MDES) jointly launched the For Your Sweetheart campaign—a nationwide endeavour to increase public awareness and to educate Malaysians about diabetes-related heart disease.

According to Dr Zanariah Hussein, president of MEMS and consultant endocrinologist at Hospital Putrajaya, discussing the common complications of diabetes is not enough anymore. She said: “Approximately 50.3 percent of deaths in people with diabetes are caused by diabetes-related heart disease. We need to address this problem urgently. Through For Your Sweetheart Campaign, we want to educate the public, especially those who are affected by diabetes, about the link between diabetes and heart disease.” [
https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/heart-disease-stroke Accessed on 14 August 2019]

While it is well known in the medical fraternity that diabetes and heart disease share a close link, awareness among the general public is still low. People with diabetes tend to develop heart disease at a younger age, compared to those without diabetes and most people, including those affected by diabetes, do not know that heart disease is the leading cause of death among people with diabetes. [Cardiovasc Diabetol. 2018;17(1):83]

According to Siah Guan Jian, president of MDES and principal diabetes educator (DE) at National Heart Institute (IJN), the diabetes educators can help to bridge the gap in understanding the link between diabetes and heart disease. Siah said: “Our role in diabetes control and management is to educate those living with diabetes about their increased risks of developing heart disease and empower them with knowledge that can help them protect their heart from further damage. Through this campaign, we encourage everyone with diabetes to speak to DEs to not just learn more about how they can control their condition better, but also protect their heart at the same time.”

Professor Chee Kok Han, who was also at the campaign launch, said diabetes affects about half of heart patients in Malaysia. Persons with diabetes are nearly twice more likely to die from heart disease or stroke compared with those without diabetes. Chee is senior consultant cardiologist at University Malaya Medical Center. [https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/heart-disease-stroke Accessed on 14 August 2019]

 




Casting the net wide

The campaign, which is supported by Boehringer Ingelheim, aims to reach as many people as possible through a multi-pronged approach. Campaign poster and educational leaflets in the three major languages will be made available at clinics and hospitals.

On the social media front, For Your Sweetheart is also teaming up with Fatimah Abu Bakar, actor and former journalist; Sharifah Aryana, actor and producer; and Sharifah Amani, actor, writer and director. They will serve as advocates on social media.

A social experiment was carried out by MEMS and MDES to determine Malaysians’ knowledge about the diabetes-heart disease link. The result of the experiment can be viewed at the campaign website
foryoursweetheart.my. Two patient stories detailing their experiences living with diabetes can also be accessed on the website.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.